Related Experiment Video
Updated: Jun 25, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR
Yajing Zhang1,2,3, Fangfang Cheng1, Biping Deng4
1Innovative Medical Center for Oncology & Immunology, Beijing GoBroad Boren Hospital, Beijing, China.
Hematological Oncology
|June 24, 2026
Summary
CD19 CAR T-cell therapy offers a promising new treatment for refractory idiopathic multicentric Castleman disease (iMCD). A patient with iMCD-IPL achieved a complete remission lasting over 12 months after this innovative therapy.
Area of Science:
- Hematology
- Immunotherapy
- Oncology
Background:
- Idiopathic multicentric Castleman disease (iMCD) is a rare, life-threatening condition.
- Current first-line therapy, siltuximab, is ineffective for a significant portion of patients, leading to refractory disease or relapse.
- Idiopathic plasmacytic lymphadenopathy (IPL) is a subtype of iMCD.